Volume 30, Number 3—March 2024
CME ACTIVITY - Research
Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection
Table 1
Demographic, clinical, laboratory, and therapeutic characteristics of DL and CL patients in study of leishmaniasis immune response and clinical and therapeutic outcomes, Corte de Pedra Health Post, Brazil, 2016–2019*
Characteristic | DL, n = 101 | CL, n = 101 | p value |
---|---|---|---|
Age, y |
39.5 + 14.8 |
32 + 13.3 |
0.0002† |
Sex, no. (%) patients. | |||
M | 88 (87) | 69 (68) | 0.04‡ |
F |
13 (13) |
23 (32) |
0.04‡ |
Duration of disease until diagnosis, d |
52.7 + 2.7 |
41 + 1.7 |
0.0003† |
No. lesions | 113.6 + 210 | 1.4 + 0.7 | <0.0001† |
Biggest lesion size, mm2 |
775.6 + 2,190 |
392.7 + 283.4 |
NS |
Lymphadenopathy, no. positive/no. tested (%) | 47/93 (50.5) | 61/101 (60.4) | NS |
LST size, mm2 | 102.3 + 96.5 | 213.6 + 126.9 | 0.0001† |
LST , no. positive/no. tested (%) | 64/97 (66) | 101/101 (100) | 0.0001‡ |
PCR. no. positive/no. tested (%) | 84/91 (92) | 101/101 (100) | NS |
Cure rate, no. cured/no. treated (%)§ | 34/78 (44)¶ | 44/101 (60) | NS |
Healing time, d§ | 177 + 19.6 | 110.8 + 7.7 | 0.001† |
*Values are mean + SD unless otherwise indicated. CL, cutaneous leishmaniasis; DL, disseminated leishmaniasis; LST, Leishmania skin test, NS, not significant. †By unpaired t-test. ‡By Fisher exact test. §After 1 standard course of meglumine antimoniate (20 mg/kg/d) for 20 d (CL) or 30 d (DL). ¶Six patients had no outcome data, irregular use, or discontinuation.